Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
15 May 2024
Historique:
received: 15 06 2023
accepted: 24 04 2024
medline: 16 5 2024
pubmed: 16 5 2024
entrez: 15 5 2024
Statut: epublish

Résumé

5q-associated spinal muscular atrophy (SMA) is a motoneuron disease caused by mutations in the survival motor neuron 1 (SMN1) gene. Adaptive immunity may contribute to SMA as described in other motoneuron diseases, yet mechanisms remain elusive. Nusinersen, an antisense treatment, enhances SMN2 expression, benefiting SMA patients. Here we have longitudinally investigated SMA and nusinersen effects on local immune responses in the cerebrospinal fluid (CSF) - a surrogate of central nervous system parenchyma. Single-cell transcriptomics (SMA: N = 9 versus Control: N = 9) reveal NK cell and CD8+ T cell expansions in untreated SMA CSF, exhibiting activation and degranulation markers. Spatial transcriptomics coupled with multiplex immunohistochemistry elucidate cytotoxicity near chromatolytic motoneurons (N = 4). Post-nusinersen treatment, CSF shows unaltered protein/transcriptional profiles. These findings underscore cytotoxicity's role in SMA pathogenesis and propose it as a therapeutic target. Our study illuminates cell-mediated cytotoxicity as shared features across motoneuron diseases, suggesting broader implications.

Identifiants

pubmed: 38750052
doi: 10.1038/s41467-024-48195-3
pii: 10.1038/s41467-024-48195-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4120

Informations de copyright

© 2024. The Author(s).

Références

Mercuri, E., Sumner, C. J., Muntoni, F., Darras, B. T. & Finkel, R. S. Spinal muscular atrophy. Nat. Rev. Dis. Prim. 8, 52 (2022).
pubmed: 35927425 doi: 10.1038/s41572-022-00380-8
Wirth, B. Spinal muscular atrophy: in the challenge lies a solution. Trends Neurosci. 44, 306–322 (2021).
pubmed: 33423791 doi: 10.1016/j.tins.2020.11.009
Lefebvre, S. et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 16, 265–269 (1997).
pubmed: 9207792 doi: 10.1038/ng0797-265
Calucho, M. et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul. Disord. 28, 208–215 (2018).
pubmed: 29433793 doi: 10.1016/j.nmd.2018.01.003
Schmitt, L.-I. et al. Spinal astrocyte dysfunction drives motor neuron loss in late-onset spinal muscular atrophy. Acta Neuropathol. 145, 611–635 (2023).
pubmed: 36930296 pmcid: 10119066 doi: 10.1007/s00401-023-02554-4
Papadimitriou, D. et al. Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol. Dis. 37, 493–502 (2010).
pubmed: 19833209 doi: 10.1016/j.nbd.2009.10.005
Tarabal, O. et al. Mechanisms involved in spinal cord central synapse loss in a mouse model of spinal muscular atrophy. J. Neuropathol. Exp. Neurol. 73, 519–535 (2014).
pubmed: 24806302 doi: 10.1097/NEN.0000000000000074
Kim, E. K. & Choi, E.-J. SMN1 functions as a novel inhibitor for TRAF6-mediated NF-κB signaling. Biochim. Biophys. Acta Mol. Cell Res. 1864, 760–770 (2017).
pubmed: 28214532 doi: 10.1016/j.bbamcr.2017.02.011
McGivern, J. V. et al. Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production. Glia 61, 1418–1428 (2013).
pubmed: 23839956 pmcid: 3941074 doi: 10.1002/glia.22522
Vukojicic, A. et al. The classical complement pathway mediates microglia-dependent remodeling of spinal motor circuits during development and in SMA. Cell Rep. 29, 3087–3100.e7 (2019).
pubmed: 31801075 pmcid: 6937140 doi: 10.1016/j.celrep.2019.11.013
Lesbordes, J.-C. et al. Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy. Hum. Mol. Genet. 12, 1233–1239 (2003).
pubmed: 12761038 doi: 10.1093/hmg/ddg143
Araki, S. et al. Neuropathological analysis in spinal muscular atrophy type II. Acta Neuropathol. 106, 441–448 (2003).
pubmed: 12898156 doi: 10.1007/s00401-003-0743-9
Kuru, S. et al. An autopsy case of spinal muscular atrophy type III (Kugelberg-Welander disease). Neuropathology 29, 63–67 (2009).
pubmed: 18410269 doi: 10.1111/j.1440-1789.2008.00910.x
Deguise, M.-O. et al. Immune dysregulation may contribute to disease pathogenesis in spinal muscular atrophy mice. Hum. Mol. Genet. 26, 801–819 (2017).
pubmed: 28108555 pmcid: 5409095
Thomson, A. K. et al. Survival of motor neurone protein is required for normal postnatal development of the spleen. J. Anat. 230, 337–346 (2017).
pubmed: 27726134 doi: 10.1111/joa.12546
Khairallah, M.-T. et al. SMN deficiency negatively impacts red pulp macrophages and spleen development in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 26, 932–941 (2017).
pubmed: 28062667 pmcid: 6075362
Uhlen, M. et al. A genome-wide transcriptomic analysis of protein-coding genes in human blood cells. Science 366, eaax9198 (2019).
pubmed: 31857451 doi: 10.1126/science.aax9198
Garofalo, S. et al. Natural killer cells modulate motor neuron-immune cell cross talk in models of amyotrophic lateral sclerosis. Nat. Commun. 11, 1773 (2020).
pubmed: 32286313 pmcid: 7156729 doi: 10.1038/s41467-020-15644-8
Yazdani, S. et al. T cell responses at diagnosis of amyotrophic lateral sclerosis predict disease progression. Nat. Commun. 13, 6733 (2022).
pubmed: 36347843 pmcid: 9643478 doi: 10.1038/s41467-022-34526-9
Campisi, L. et al. Clonally expanded CD8 T cells characterize amyotrophic lateral sclerosis-4. Nature 606, 945–952 (2022).
pubmed: 35732742 pmcid: 10089623 doi: 10.1038/s41586-022-04844-5
Abati, E., Citterio, G., Bresolin, N., Comi, G. P. & Corti, S. Glial cells involvement in spinal muscular atrophy: could SMA be a neuroinflammatory disease? Neurobiol. Dis. 140, 104870 (2020).
pubmed: 32294521 doi: 10.1016/j.nbd.2020.104870
Mercuri, E., Pera, M. C., Scoto, M., Finkel, R. & Muntoni, F. Spinal muscular atrophy – insights and challenges in the treatment era. Nat. Rev. Neurol. 16, 706–715 (2020).
pubmed: 33057172 doi: 10.1038/s41582-020-00413-4
Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723–1732 (2017).
pubmed: 29091570 doi: 10.1056/NEJMoa1702752
Scheijmans, F. E. V. et al. Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment. Eur. J. Paediatr. Neurol. 42, 34–41 (2022).
pubmed: 36525882 doi: 10.1016/j.ejpn.2022.12.003
Nuzzo, T. et al. Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients. Commun. Med. 3, 28 (2023).
pubmed: 36792810 pmcid: 9932014 doi: 10.1038/s43856-023-00256-2
Bonanno, S. et al. Identification of a cytokine profile in serum and cerebrospinal fluid of pediatric and adult spinal muscular atrophy patients and its modulation upon nusinersen treatment. Front. Cell. Neurosci. 16, 982760 (2022).
pubmed: 36035258 pmcid: 9406526 doi: 10.3389/fncel.2022.982760
Freigang, M. et al. Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy. Orphanet J. Rare Dis. 16, 330 (2021).
pubmed: 34321067 pmcid: 8320162 doi: 10.1186/s13023-021-01961-8
Heming, M., Börsch, A.-L., Wiendl, H. & Meyer Zu Hörste, G. High-dimensional investigation of the cerebrospinal fluid to explore and monitor CNS immune responses. Genome Med. 14, 94 (2022).
pubmed: 35978442 pmcid: 9385102 doi: 10.1186/s13073-022-01097-9
Meyer Zu Hörste, G., Gross, C. C., Klotz, L., Schwab, N. & Wiendl, H. Next-generation neuroimmunology: new technologies to understand central nervous system autoimmunity. Trends Immunol. 41, 341–354 (2020).
pubmed: 32147112 doi: 10.1016/j.it.2020.02.005
Gate, D. et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease. Nature 577, 399–404 (2020).
pubmed: 31915375 pmcid: 7445078 doi: 10.1038/s41586-019-1895-7
Coque, E. et al. Cytotoxic CD8+ T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc. Natl Acad. Sci. USA 116, 2312–2317 (2019).
pubmed: 30674678 pmcid: 6369778 doi: 10.1073/pnas.1815961116
Biogen Inc. Spinraza prescribing information Document at https://www.spinraza.com/content/dam/commercial/spinraza/caregiver/en_us/pdf/spinraza-prescribing-information.pdf (2017).
Schafflick, D. et al. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat. Commun. 11, 247 (2020).
pubmed: 31937773 pmcid: 6959356 doi: 10.1038/s41467-019-14118-w
Heming, M. et al. Neurological manifestations of COVID-19 feature T cell exhaustion and dedifferentiated monocytes in cerebrospinal fluid. Immunity 54, 164–175.e6 (2021).
pubmed: 33382973 doi: 10.1016/j.immuni.2020.12.011
Ramesh, A. et al. A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. Proc. Natl Acad. Sci. USA 117, 22932–22943 (2020).
pubmed: 32859762 pmcid: 7502747 doi: 10.1073/pnas.2008523117
Pappalardo, J. L. et al. Transcriptomic and clonal characterization of T cells in the human central nervous system. Sci. Immunol. 5, eabb8786 (2020).
pubmed: 32948672 pmcid: 8567322 doi: 10.1126/sciimmunol.abb8786
Jongstra, J. et al. The isolation and sequence of a novel gene from a human functional T cell line. J. Exp. Med. 165, 601–614 (1987).
pubmed: 2434598 doi: 10.1084/jem.165.3.601
Krensky, A. M. & Clayberger, C. Biology and clinical relevance of granulysin. Tissue Antigens 73, 193–198 (2009).
pubmed: 19254247 pmcid: 2679253 doi: 10.1111/j.1399-0039.2008.01218.x
Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1088 (2021).
pubmed: 33597522 pmcid: 7889871 doi: 10.1038/s41467-021-21246-9
Ihim, S. A. et al. Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: biological role in induction, regulation, and treatment. Front. Immunol. 13, 919973 (2022).
pubmed: 36032110 pmcid: 9410767 doi: 10.3389/fimmu.2022.919973
Vallejo, A. F. et al. snPATHO-Seq: Unlocking the FFPE Archives for Single Nucleus RNA Profiling. https://doi.org/10.1101/2022.08.23.505054 . (2022).
Zhu, B. et al. Single-Cell Transcriptomic and Proteomic Analysis of Parkinson’s Disease Brains. https://doi.org/10.1101/2022.02.14.480397 . (2022).
Lake, J., Storm, C. S., Makarious, M. B. & Bandres-Ciga, S. Genetic and transcriptomic biomarkers in neurodegenerative diseases: current situation and the road ahead. Cells 10, 1030 (2021).
pubmed: 33925602 pmcid: 8170880 doi: 10.3390/cells10051030
Weydt, P. et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann. Neurol. 79, 152–158 (2016).
pubmed: 26528863 doi: 10.1002/ana.24552
Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492–501 (2001).
pubmed: 11433374 doi: 10.1038/35081564
Yeh, F. L., Hansen, D. V. & Sheng, M. TREM2, microglia, and neurodegenerative diseases. Trends Mol. Med. 23, 512–533 (2017).
pubmed: 28442216 doi: 10.1016/j.molmed.2017.03.008
Khayrullina, G. et al. Survival motor neuron protein deficiency alters microglia reactivity. Glia 70, 1337–1358 (2022).
pubmed: 35373853 pmcid: 9081169 doi: 10.1002/glia.24177
Wyss-Coray, T. et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 7, 612–618 (2001).
pubmed: 11329064 doi: 10.1038/87945
Caraci, F. et al. Dysfunction of TGF-β1 signaling in Alzheimer’s disease: perspectives for neuroprotection. Cell Tissue Res. 347, 291–301 (2012).
pubmed: 21879289 doi: 10.1007/s00441-011-1230-6
McArthur, S. et al. Annexin A1: a central player in the anti-inflammatory and neuroprotective role of microglia. J. Immunol. 185, 6317–6328 (2010).
pubmed: 20962261 doi: 10.4049/jimmunol.1001095
Krzywinski, M. & Altman, N. Comparing samples—part II. Nat. Methods 11, 355–356 (2014).
doi: 10.1038/nmeth.2900
Felderhoff-Mueser, U., Schmidt, O. I., Oberholzer, A., Bührer, C. & Stahel, P. F. IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci. 28, 487–493 (2005).
pubmed: 16023742 doi: 10.1016/j.tins.2005.06.008
Menge, T., Jander, S. & Stoll, G. Induction of the proinflammatory cytokine interleukin-18 by axonal injury. J. Neurosci. Res. 65, 332–339 (2001).
pubmed: 11494369 doi: 10.1002/jnr.1158
Schmidt, O. I. et al. Tumor necrosis factor-mediated inhibition of interleukin-18 in the brain: a clinical and experimental study in head-injured patients and in a murine model of closed head injury. J. Neuroinflammation 1, 13 (2004).
pubmed: 15285802 pmcid: 506787 doi: 10.1186/1742-2094-1-13
Italiani, P. et al. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J. Neuroinflammation 11, 94 (2014).
pubmed: 24884937 pmcid: 4039322 doi: 10.1186/1742-2094-11-94
Hartlehnert, M. et al. Bcl6 controls meningeal Th17-B cell interaction in murine neuroinflammation. Proc. Natl Acad. Sci. USA 118, e2023174118 (2021).
pubmed: 34479995 pmcid: 8433502 doi: 10.1073/pnas.2023174118
Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587.e29 (2021).
pubmed: 34062119 pmcid: 8238499 doi: 10.1016/j.cell.2021.04.048
Young, M. D. & Behjati, S. SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data. GigaScience 9, giaa151 (2020).
pubmed: 33367645 pmcid: 7763177 doi: 10.1093/gigascience/giaa151
Germain, P.-L., Lun, A., Garcia Meixide, C., Macnair, W. & Robinson, M. D. Doublet identification in single-cell sequencing data using scDblFinder. F1000Research 10, 979 (2021).
pubmed: 35814628 doi: 10.12688/f1000research.73600.1
Choudhary, S. & Satija, R. Comparison and evaluation of statistical error models for scRNA-seq. Genome Biol. 23, 27 (2022).
pubmed: 35042561 pmcid: 8764781 doi: 10.1186/s13059-021-02584-9
Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289–1296 (2019).
pubmed: 31740819 pmcid: 6884693 doi: 10.1038/s41592-019-0619-0
Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902.e21 (2019).
pubmed: 31178118 pmcid: 6687398 doi: 10.1016/j.cell.2019.05.031
Phipson, B. et al. propeller: testing for differences in cell type proportions in single cell data. Bioinformatics 38, 4720–4726 (2022).
pubmed: 36005887 pmcid: 9563678 doi: 10.1093/bioinformatics/btac582
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
pubmed: 25605792 pmcid: 4402510 doi: 10.1093/nar/gkv007
Liu, R. et al. Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses. Nucleic Acids Res. 43, e97 (2015).
pubmed: 25925576 pmcid: 4551905 doi: 10.1093/nar/gkv412
Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90–W97 (2016).
pubmed: 27141961 pmcid: 4987924 doi: 10.1093/nar/gkw377
Borcherding, N., Bormann, N. L. & Kraus, G. scRepertoire: an R-based toolkit for single-cell immune receptor analysis. F1000Research 9, 47 (2020).
pubmed: 32789006 pmcid: 7400693 doi: 10.12688/f1000research.22139.1
Willemsen, M., Krebbers, G., Bekkenk, M. W., Teunissen, M. B. M. & Luiten, R. M. Improvement of Opal multiplex immunofluorescence workflow for human tissue sections. J. Histochem. Cytochem. 69, 339–346 (2021).
pubmed: 33797290 pmcid: 8091416 doi: 10.1369/00221554211007793
König, S. et al. Topographic protein profiling of the age-related proteome in the retinal pigment epithelium of Callithrix jacchus with respect to macular degeneration. J. Proteom. 191, 1–15 (2019).
doi: 10.1016/j.jprot.2018.05.016
Ge, S. X., Jung, D. & Yao, R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics 36, 2628–2629 (2020).
pubmed: 31882993 doi: 10.1093/bioinformatics/btz931
Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543–D552 (2022).
pubmed: 34723319 doi: 10.1093/nar/gkab1038

Auteurs

I-Na Lu (IN)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Phyllis Fung-Yi Cheung (PF)

Spatiotemporal Tumor Heterogeneity, German Cancer Consortium (DKTK), Partner Site Essen, A Partnership Between German Cancer Research Center (DKFZ) and University Hospital Essen, Essen, Germany.
Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Division of Solid Tumor Translational Oncology, DKTK, Partner Site Essen, A Partnership Between German Cancer Research Center (DKFZ) and University Hospital Essen, Essen, Germany.

Michael Heming (M)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Christian Thomas (C)

Institute of Neuropathology, University Hospital Münster, Münster, Germany.

Giovanni Giglio (G)

Spatiotemporal Tumor Heterogeneity, German Cancer Consortium (DKTK), Partner Site Essen, A Partnership Between German Cancer Research Center (DKFZ) and University Hospital Essen, Essen, Germany.
Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Division of Solid Tumor Translational Oncology, DKTK, Partner Site Essen, A Partnership Between German Cancer Research Center (DKFZ) and University Hospital Essen, Essen, Germany.

Markus Leo (M)

Department of Neurology and Center for Translational Neuro and Behavioral Science, University Hospital Essen, Essen, Germany.

Merve Erdemir (M)

Department of Neurology and Center for Translational Neuro and Behavioral Science, University Hospital Essen, Essen, Germany.

Timo Wirth (T)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Simone König (S)

Core Unit Proteomics, Interdisciplinary Center for Clinical Research, University of Münster, Münster, Germany.

Christine A Dambietz (CA)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Christina B Schroeter (CB)

Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Christopher Nelke (C)

Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Jens T Siveke (JT)

Spatiotemporal Tumor Heterogeneity, German Cancer Consortium (DKTK), Partner Site Essen, A Partnership Between German Cancer Research Center (DKFZ) and University Hospital Essen, Essen, Germany.
Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Division of Solid Tumor Translational Oncology, DKTK, Partner Site Essen, A Partnership Between German Cancer Research Center (DKFZ) and University Hospital Essen, Essen, Germany.

Tobias Ruck (T)

Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Luisa Klotz (L)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Carmen Haider (C)

Division of Neuropathology and Neurochemistry, Medical University of Vienna, Vienna, Austria.
Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.

Romana Höftberger (R)

Division of Neuropathology and Neurochemistry, Medical University of Vienna, Vienna, Austria.
Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.

Christoph Kleinschnitz (C)

Department of Neurology and Center for Translational Neuro and Behavioral Science, University Hospital Essen, Essen, Germany.

Heinz Wiendl (H)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Tim Hagenacker (T)

Department of Neurology and Center for Translational Neuro and Behavioral Science, University Hospital Essen, Essen, Germany. tim.hagenacker@uk-essen.de.

Gerd Meyer Zu Horste (G)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany. gerd.meyerzuhoerste@ukmuenster.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH